Drug Trial Radar · NCT03340675
Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Oct 19, 2020
Primary completion
Mar 6, 2024
Study completion Jan 23, 2026
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Vanderbilt University Medical Center
- First posted
- Nov 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respiratory care have unmasked CM as the leading cause of death. As there are yet no specific cardiac treatments to extend life, the current study aims to address this unmet medical need using a new therapeutic strategy for patients with DMD. Funding Source - FDA OOPD
Conditions
- Duchenne Muscular Dystrophy Cardiomyopathy
- Cardiomyopathy, Dilated
Interventions
IfetrobanDrug
Weight based, once daily oral ifetroban
PlaceboDrug
Matching oral placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: Baseline through 12 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
Mattel Children's Hospital
Los Angeles, California
Children's National Hospital
Washington D.C., District of Columbia
Children's Healthcare of Atlanta
Atlanta, Georgia
Lurie Children's Hospital
Chicago, Illinois
Riley Children's Hospital
Indianapolis, Indiana
Kennedy Krieger Institute
Baltimore, Maryland
Saint. Louis Children's Hospital
St Louis, Missouri
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Monroe Carrell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.